Ally Bridge Group NY LLC cut its stake in Alumis Inc. (NASDAQ:ALMS - Free Report) by 32.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 418,416 shares of the company's stock after selling 200,334 shares during the quarter. Alumis comprises about 2.4% of Ally Bridge Group NY LLC's holdings, making the stock its 24th biggest holding. Ally Bridge Group NY LLC owned about 0.89% of Alumis worth $4,469,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also recently modified their holdings of the company. BNP Paribas Financial Markets purchased a new position in shares of Alumis in the third quarter worth $27,000. MetLife Investment Management LLC bought a new stake in Alumis in the 3rd quarter worth approximately $89,000. Maven Securities LTD purchased a new stake in Alumis during the 2nd quarter valued at $332,000. Charles Schwab Investment Management Inc. bought a new position in shares of Alumis during the 3rd quarter valued at $1,160,000. Finally, Millennium Management LLC purchased a new position in shares of Alumis in the 2nd quarter worth $3,376,000.
Analysts Set New Price Targets
ALMS has been the subject of a number of research reports. Robert W. Baird began coverage on Alumis in a research report on Thursday, October 31st. They set an "outperform" rating and a $25.00 price objective for the company. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Alumis in a research report on Thursday, November 14th. Baird R W raised shares of Alumis to a "strong-buy" rating in a report on Thursday, October 31st. Finally, HC Wainwright reduced their target price on shares of Alumis from $30.00 to $26.00 and set a "buy" rating for the company in a report on Thursday, November 14th. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, Alumis has an average rating of "Buy" and a consensus price target of $26.83.
View Our Latest Stock Report on Alumis
Alumis Stock Performance
ALMS stock traded up $0.32 during trading on Thursday, reaching $9.72. The company's stock had a trading volume of 39,075 shares, compared to its average volume of 149,127. The company has a fifty day moving average price of $10.94. Alumis Inc. has a 1 year low of $8.23 and a 1 year high of $13.53.
Alumis Profile
(
Free Report)
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Featured Articles
Before you consider Alumis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alumis wasn't on the list.
While Alumis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
